Electra Therapeutics Inc. (ETRA)
NASDAQ: ETRAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ETRA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $509.85M
- EPS (TTM)
- -$35.94
- Dividend yield
- None
- 52-week range
- 6.87 – 15.50
- Day range
- 8.07 – 9.65
- Volume / Avg
- 376.12K / 559.28K
- Beta
- —
- Shares outstanding
- 62.87M
52-week range
ETRA stock today
Electra Therapeutics (ETRA) closed at $8.11 on Nov 20, down 9.28% (-$0.83), versus the S&P 500's 3.70% decline. At this level, ETRA sits near the bottom of its 52-week range of $6.87 to $15.50: 47.7% below the high, set on Sep 18, 2026 and 18.0% above the low. Electra Therapeutics has posted a net loss over the last twelve months (EPS of -$35.94), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Electra Therapeutics
Company profileElectra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Quehuong Dong M.B.A., Pharm.D.
- Headquarters
- South San Francisco, CA
- Employees
- 46
- IPO year
- 2026
- Website
- electra-therapeutics.com
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$33.20+309.37%
- Strong buy 1
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-3.47 vs $-1.76
- Surprise
- -97.16%
ETRA news
All ETRA newsElectra Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VALNValneva SE ADR | 5.16 | -3.82% | $490.86M | vs ETRA |
| DNAGinkgo Bioworks Holdings Inc. Class A | 7.46 | -9.02% | $483.54M | vs ETRA |
| SANASana Biotechnology Inc. | 1.59 | -8.62% | $476.42M | vs ETRA |
| RGNXREGENXBIO Inc. | 7.16 | -0.28% | $473.44M | vs ETRA |
| FENCFennec Pharmaceuticals Inc. | 13.09 | -2.68% | $462.14M | vs ETRA |
| DBVTDBV Technologies S.A. ADR | 9.02 | -4.25% | $566.82M | vs ETRA |
| ENTXEntera Bio Ltd. | 3.31 | +0.76% | $575.53M | vs ETRA |
| FDMT4D Molecular Therapeutics Inc. | 10.23 | -4.57% | $576.76M | vs ETRA |
Indexes, lists and sector
Electra Therapeutics stock FAQ
What is Electra Therapeutics's stock price today?
ETRA last traded at $8.11 as of Nov 20, 4:00 PM EST, down 9.28% on the day. Prices are delayed at least 15 minutes.
Who is Electra Therapeutics's CEO?
Dr. Quehuong Dong M.B.A., Pharm.D. is the chief executive officer of Electra Therapeutics Inc., which has about 46 employees.
What is the ETRA 52-week high?
The 52-week high for ETRA is $15.50 and the 52-week low is $6.87. The stock is currently 47.7% below its high.